Arthneeti

Venus Remedies Q2 FY27 Share Price & Earnings Call Analysis

₹1,315.20+1.13% today
Market cap
₹1,758 Cr
P/E
14.44
ROE
15.58%
PEG
0.27
Price to sales
2.10
Debt to equity
0.02
52W high / low
₹1,947 / ₹442
Sales growth (5Y)
7.09%
EBITDA margin
21.22%
Net profit margin
12.45%
Promoter holding
41.76%
Sales (last year)
₹837 Cr

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Venus Remedies rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Financials of Venus Remedies

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Venus Remedies

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%
FIIs +1.59%1.48%1.06%1.18%1.11%1.34%2.25%1.86%2.25%2.80%2.92%3.14%
DIIs +0.00%0.00%0.00%0.00%0.00%0.00%0.11%0.75%1.03%1.20%0.89%0.74%
Public +56.65%56.76%57.17%57.06%57.13%56.90%55.89%55.62%54.95%54.24%54.44%54.37%
No. of Shareholders19,56019,91319,61419,55719,77119,98219,30717,72518,60618,40321,90522,968

Financials of Venus Remedies

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +168143195109170177195137193180259179219
Expenses +15013117697163158166122162143196145176
Operating Profit1812191181829153138633442
OPM %11%8%10%10%4.5%10%15%11%16%21%24%19%19%
Other Income +32428127323531
Interest0000000000000
Depreciation67666556677710
Profit before tax14817792531132633623033
Tax %31%12%40%82%61%21%32%24%24%24%23%24%23%
Net Profit +10711142021102026482326
EPS in Rs7.445.127.860.912.6314.6615.717.1815.0619.1435.5417.1819.19

Financials of Venus Remedies

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +455407400372322335544597552596645766837
Expenses +366326349333289295490535492537577619660
Operating Profit8981513933415462606069147178
OPM %20%20%13%11%10%12%10%10%11%10%11%19%21%
Other Income +1222-3-44381012261311
Interest41383435251313000000
Depreciation46424034343235343226232630
Profit before tax34-22-28-30-84936384572134159
Tax %-95%52%-21%11%-4%24%-27%-12%30%36%37%23%
Net Profit +52-17-31-29-106241272845103122
EPS in Rs4.511.49-13.84-24.87-23.15-8.1050.0530.4619.8821.3133.9076.9091.05
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%13%

Financials of Venus Remedies

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital11111212121212131313131313
Reserves445426376350320311388427447474548650691
Borrowings +3213353123072982205143424121212
Other Liabilities +64706582102100104979898153178123
Total Liabilities841843765751733644556580601627716854840
Fixed Assets +444452406389364289262241216219229232217
CWIP78806665652525252621265175
Investments00000000201984238240
Other Assets +319310293297304330269314339368376333307
Total Assets841843765751733644556580601627716854840

Financials of Venus Remedies

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +68475931457813241373786156
Cash from Investing Activity +-673-188-11-557-17-58-8-77-185
Cash from Financing Activity +-1-46-44-39-35-73-162-9-1-1-1-3
Net Cash Flow-13-40-1-02714-22289-32
Free Cash Flow59464119357013241292469118
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit76%58%116%79%139%190%245%66%61%89%148%129%

Financials of Venus Remedies

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days515543464333212451496449
Inventory Days19421922624628629612911813212597122
Days Payable4038485272777647565589107
Cash Conversion Cycle20423622124025725274951271207264
Working Capital Days54695425-17371821091188662
ROCE %6%5%2%1%1%2%8%8%8%9%11%21%
39out of 100

Momentum score · price trend

39 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+199.4%98%
Last 6 months+32.2%83%
Last 3 months−17.9%24%

The price is 33.2% below its all-time high of ₹1,947 (25 Jun 2026). Stocks more than 20% below their peak have their score halved, so 77 became 39.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Venus Remedies: 0.4 × 98 + 0.4 × 83 + 0.2 × 24 = 77, halved to 39 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Venus Remedies's management said in earlier quarters